MDWD vs VCEL
MDWD: MediWound develops enzymatic biotherapies that debride wounds and burns by removing dead tissue, targeting faster healing with biological precision. VCEL: Vericel is a leader in advanced autologous cell therapies for sports medicine and severe burn care, with FDA-approved products MACI for cartilage repair and Epicel for severe burns.
Side-by-side fundamentals
| Metric | MDWD | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.42 | $44.56 | |
| Market cap as of 2026-07-23 | $183M | $2.4B | |
| P/E as of 2026-07-23 | n/a | 109.79 | |
| PEG as of 2026-07-23 | -0.77 | 0.12 | MDWD lower |
| Net margin as of 2026-07-23 | -180.3% | +7.3% | VCEL higher |
| Gross margin as of 2026-07-23 | +19.6% | +74.8% | VCEL higher |
| Operating margin as of 2026-07-23 | -193.5% | +5.4% | VCEL higher |
| ROE as of 2026-07-23 | -67.2% | +6.4% | VCEL higher |
| ROA as of 2026-07-23 | -31.9% | +4.6% | VCEL higher |
| Debt / equity as of 2026-07-23 | 0.20 | 0.00 | VCEL lower |
| Revenue growth (YoY) as of 2026-07-23 | -24.6% | +22.4% | VCEL higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +18.9% | |
| Beta as of 2026-07-23 | 0.14 | 1.08 | |
| 1-year return as of 2026-07-22 close | -29.6% | +17.3% | VCEL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.